Mansi J, Ellis E, Viner C, Mundy J, Smith T, Millar J, Milan S, Gore M, Cunningham D
CRC Section of Medicine, Institute of Cancer Research, Sutton, Surrey, U.K.
Cancer Chemother Pharmacol. 1992;30(2):149-51. doi: 10.1007/BF00686408.
A "priming" injection of cyclophosphamide (400 mg/m2 given i.v. on day -7) has been shown to reduce intestinal permeability and thus gut toxicity in patients receiving high-dose melphalan. To determine the optimal timing for this injection, patients receiving 200 mg/m2 melphalan with an autologous bone marrow transplant were randomly assigned to receive cyclophosphamide at 5, 7 or 9 days before the melphalan. The median percentage of [51Cr]-ethylenediaminetetraacetic acid excretion was similar (9.1% vs 7.1% vs 7.7%, respectively), with equivalent duration of WHO grade 2-4 mucositis and diarrhoea being recorded for each group. Thus, the timing of the cyclophosphamide prime is not critical, and the priming injection may be given between 5 and 9 days prior to high-dose melphalan.
已证明，“预充”注射环磷酰胺（在第-7天静脉注射400mg/m²）可降低接受大剂量美法仑治疗患者的肠道通透性，从而减轻肠道毒性。为确定该注射的最佳时间，将接受200mg/m²美法仑及自体骨髓移植的患者随机分为三组，分别在美法仑给药前5天、7天或9天接受环磷酰胺注射。[51Cr]-乙二胺四乙酸排泄的中位数百分比相似（分别为9.1%、7.1%和7.7%），每组记录的WHO 2-4级粘膜炎和腹泻持续时间相当。因此，环磷酰胺预充的时间并不关键，预充注射可在大剂量美法仑给药前5至9天进行。
